Skip to main content
Premium Trial:

Request an Annual Quote

Tm Bio Shareholders to Vote on Luminex Buy on Feb. 23

NEW YORK (GenomeWeb News) — Tm Bioscience shareholder will vote on Feb. 23 to decide whether Luminex will acquire the company, Tm said today.
 
Luminex said on Dec. 15 it had agreed in principle to purchase Tm in a stock-for-stock deal in which Luminex would buy a 41.5 percent stake in Tm. Luminex said it plans to deliver Tm’s kits and reagents to wider markets through its business channels.
 
Tm, based in Toronto, said a superior court in Ontario has approved the vote and, should the company’s shareholders approve the deal, the court will consider the acquisition on Feb. 27.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.